Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: KCP
Name: kielin cysteine rich BMP regulator
Location: 07q32.1
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT01986348 Study Evaluating the Efficacy and Safety of Selinexor KPT-330 in Participants With Recurrent Gliomas View
NCT02606461 Selinexor in Advanced Liposarcoma View
NCT02431364 Trial of Safety and Tolerability of Oral Verdinexor KPT-335 in Healthy Adults View
NCT02336815 Selinexor Treatment of Refractory Myeloma View
NCT01607892 Safety Study of the Selective Inhibitor of Nuclear Export SINE KPT-330 in Patients With Advanced Hematological Cancer View
NCT01607905 Safety Study of KPT-330 Selinexor in Patients With Advanced or Metastatic Solid Tumor Cancer View
NCT02649790 Study of the Safety Tolerability and Efficacy of KPT-8602 in Participants With RelapsedRefractory Cancer Indications View
NCT02343042 Selinexor and Backbone Treatments of Multiple Myeloma Patients View
NCT01333826 Schooling Income and HIV Risk in Malawi View
NCT02367690 Study of Safety Tolerability and Pharmacokinetics of Topical Selinexor KPT-330 Diabetic Foot Ulcer DFU Patients View
NCT03110562 Bortezomib Selinexor and Dexamethasone in Patients With Multiple Myeloma View
NCT01896505 A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma View
NCT02227251 Selinexor KPT-330 in Patients With RelapsedRefractory Diffuse Large B-Cell Lymphoma DLBCL View
NCT02389543 Study of Selinexor KPT- 330 Lenalidomide Dexamethasone in RelapsedRefractory Multiple Myeloma Patients View
NCT02431351 Efficacy Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients View
NCT03555422 Maintenance with SelinexorPlacebo After Combination Chemotherapy in Participants with Endometrial Cancer SIENDO View
NCT02628704 Selinexor Carfilzomib and Dexamethasone Versus Placebo Carfilzomib and Dexamethasone in Multiple Myeloma View
NCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum R-GDP with or Without Selinexor in Patients with RelapsedRefractory Diffuse Large B-cell Lymphoma View
NCT04256707 Relative BioavailabilityBioequivalence of Different Formulations of Selinexor the Impact of Hepatic Impairment on Selinexor Pharmacokinetics Tolerability and Antitumor Activity of Selinexor Combination Treatment View
NCT02025985 Study of KPT-330 Selinexor in Female Patients With Advanced Gynaecologic Malignancies View
NCT02088541 Selinexor KPT-330 in Older Patients With Relapsed AML View
NCT02138786 Selinexor in Initial or Refractory andor Relapsed Richters Transformation View
NCT02146833 SHIP Selinexor in Hormone Insensitive Prostate Cancer View
NCT01546961 Chloroquine Population Pharmacokinetics in Pre and Post-partum Women View
NCT02213133 Selinexor Treatment of Advanced RelapsedRefractory Squamous Cell Carcinomas View
NCT02314247 Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma View
NCT02702492 PAK4 and NAMPT in Patients With Solid Malignancies or NHL PANAMA View